NovoCure NVCR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $174.06M-0.2% | $174.35M+4.3% | $167.2M+5.3% | $158.81M+2.5% | $154.99M-3.9% | ||
| $38.93M-7.7% | $42.16M-5.8% | $44.73M+7.9% | $41.47M+7.7% | $38.52M+15.1% | ||
| $135.13M+2.2% | $132.19M+7.9% | $122.48M+4.4% | $117.33M+0.7% | $116.47M-8.9% | ||
| 77.6%+1.8pp | 75.8%+2.6pp | 73.2%-0.6pp | 73.9%-1.3pp | 75.1%-4.1pp | ||
| $58.34M-4.2% | $60.91M+12.7% | $54.03M-3.2% | $55.83M+3.8% | $53.78M+5.0% | ||
| $58.36M-15.0% | $68.66M+17.3% | $58.55M+2.6% | $57.07M+2.3% | $55.79M-17.2% | ||
| $85.85M+99.6% | $43.02M-6.3% | $45.92M+4.5% | $43.96M-1.8% | $44.77M-38.2% | ||
| $202.55M+17.4% | $172.59M+8.9% | $158.5M+1.0% | $156.85M+1.6% | $154.34M-19.2% | ||
| $202.55M+17.4% | $172.59M+8.9% | $158.5M+1.0% | $156.85M+1.6% | $154.34M-19.2% | ||
| -$67.42M-66.9% | -$40.39M-12.1% | -$36.02M+8.9% | -$39.52M-4.4% | -$37.87M+40.2% | ||
| -38.7%-15.6pp | -23.2%-1.6pp | -21.5%+3.3pp | -24.9%-0.5pp | -24.4%+14.8pp | ||
| -$1.84M— | $0-100% | $6M+32.1% | $4.54M-40.0% | $7.57M-6.5% | ||
| -$69.26M-69.1% | -$40.95M-36.4% | -$30.02M+14.2% | -$34.98M-15.5% | -$30.3M+45.1% | ||
| $1.88M+111% | -$16.46M-327% | $7.25M+40.5% | $5.16M+28.2% | $4.02M-62.4% | ||
| -$71.14M-190% | -$24.5M+34.3% | -$37.27M+7.1% | -$40.14M-17.0% | -$34.32M+47.9% | ||
| -40.9%-26.8pp | -14.1%+8.2pp | -22.3%+3.0pp | -25.3%-3.1pp | -22.1%+18.7pp | ||
| -$0.62-182% | -$0.22+33.3% | -$0.33+8.3% | -$0.36-16.1% | -$0.31+49.2% | ||
| -$0.62-182% | -$0.22+33.3% | -$0.33+8.3% | -$0.36-16.1% | -$0.31+49.2% | ||
| 114.1M+2.4% | 111.5M-0.4% | 111.9M+0.3% | 111.6M+1.2% | 110.3M+2.3% | ||
| 114.1M+2.4% | 111.5M-0.4% | 111.9M+0.3% | 111.6M+1.2% | 110.3M+2.3% | ||
| -$1.84M— | $0-100% | $6M+32.1% | $4.54M-40.0% | $7.57M-6.5% | ||
| -$67.42M-66.9% | -$40.39M-12.1% | -$36.02M+8.9% | -$39.52M-4.4% | -$37.87M+40.2% | ||
| -$63.3M-75.0% | -$36.18M-11.8% | -$32.36M+10.3% | -$36.08M-4.4% | -$34.54M+42.6% | ||
| -$63.3M-75.0% | -$36.18M-11.8% | -$32.36M+10.3% | -$36.08M-4.4% | -$34.54M+42.6% | ||
| -36.4%-15.6pp | -20.7%-1.4pp | -19.4%+3.4pp | -22.7%-0.4pp | -22.3%+15.0pp | ||
| -$67.42M-66.9% | -$40.39M-12.1% | -$36.02M+8.9% | -$39.52M-4.4% | -$37.87M+40.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is NovoCure's revenue?
- NovoCure (NVCR) generated $674.4M in revenue over the trailing twelve months, up 8.5% year over year.
- Is NovoCure profitable?
- NovoCure is not currently profitable: it reported a net loss of $173.0M over the trailing twelve months, a -25.7% net margin.
- What are NovoCure's profit margins?
- Gross margin is 75.2% and operating margin is -27.2%, with a -25.7% net margin.
- What is NovoCure's earnings per share?
- NovoCure's diluted EPS over the trailing twelve months is $-1.53.
- Where does NovoCure's income statement data come from?
- Every line is extracted from NovoCure's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
